BACKGROUND: Impulsivity is genetically correlated with, and precedes, addictive behaviors and alcoholism. If impulsivity or attention is causally related to addiction, certain pharmacological manipulations of impulsivity and/or attention may affect alcohol drinking, and vice versa. The current studies were designed to explore the relationship among impulsivity, drinking, and vigilance in selectively bred High Alcohol Preferring (HAP) mice, a line that has previously demonstrated both high impulsivity and high alcohol consumption. Amphetamine, naltrexone, and memantine were tested in a delay discounting (DD) task for their effects on impulsivity and vigilance. The same drugs and doses were also assessed for effects on alcohol drinking in a 2-bottle choice test. METHODS: HAP mice were subjected to a modified version of adjusting amount DD using 0.5-second and 10-second delays to detect decreases and increases, respectively, in impulsive responding. In 2 experiments, mice were given amphetamine (0.4, 0.8, or 1.2 mg/kg), naltrexone (3 and 10 mg/kg), and memantine (1 and 5 mg/kg) before DD testing. Another pair of studies used scheduled access, 2-bottle choice drinking to assess effects of amphetamine (0.4, 1.2, or 3.0 mg/kg), naltrexone (3 and 10 mg/kg), and memantine (1 and 5 mg/kg) on alcohol consumption. RESULTS: Amphetamine dose-dependently reduced impulsivity and vigilance decrement in DD, but similar doses left alcohol drinking unaffected. Naltrexone and memantine decreased alcohol intake at doses that did not affect water drinking but had no effects on impulsivity or vigilance decrement in the DD task. CONCLUSIONS: Contrary to our hypothesis, none of the drugs tested here, while effective on either alcohol drinking or impulsivity, decreased both behaviors. These findings suggest that the genetic association between drinking and impulsivity observed in this population is mediated by mechanisms other than those targeted by the drugs tested in these studies.
BACKGROUND: Impulsivity is genetically correlated with, and precedes, addictive behaviors and alcoholism. If impulsivity or attention is causally related to addiction, certain pharmacological manipulations of impulsivity and/or attention may affect alcohol drinking, and vice versa. The current studies were designed to explore the relationship among impulsivity, drinking, and vigilance in selectively bred High Alcohol Preferring (HAP) mice, a line that has previously demonstrated both high impulsivity and high alcohol consumption. Amphetamine, naltrexone, and memantine were tested in a delay discounting (DD) task for their effects on impulsivity and vigilance. The same drugs and doses were also assessed for effects on alcohol drinking in a 2-bottle choice test. METHODS: HAP mice were subjected to a modified version of adjusting amount DD using 0.5-second and 10-second delays to detect decreases and increases, respectively, in impulsive responding. In 2 experiments, mice were given amphetamine (0.4, 0.8, or 1.2 mg/kg), naltrexone (3 and 10 mg/kg), and memantine (1 and 5 mg/kg) before DD testing. Another pair of studies used scheduled access, 2-bottle choice drinking to assess effects of amphetamine (0.4, 1.2, or 3.0 mg/kg), naltrexone (3 and 10 mg/kg), and memantine (1 and 5 mg/kg) on alcohol consumption. RESULTS:Amphetamine dose-dependently reduced impulsivity and vigilance decrement in DD, but similar doses left alcohol drinking unaffected. Naltrexone and memantine decreased alcohol intake at doses that did not affect water drinking but had no effects on impulsivity or vigilance decrement in the DD task. CONCLUSIONS: Contrary to our hypothesis, none of the drugs tested here, while effective on either alcohol drinking or impulsivity, decreased both behaviors. These findings suggest that the genetic association between drinking and impulsivity observed in this population is mediated by mechanisms other than those targeted by the drugs tested in these studies.
Authors: Bruno Ribeiro Do Couto; Maria A Aguilar; Carmen Manzanedo; Marta Rodríguez-Arias; Jose Miñarro Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2004-09 Impact factor: 5.067
Authors: Joseph Biederman; James M Swanson; Sharon B Wigal; Christopher J Kratochvil; Samuel W Boellner; Craig Q Earl; John Jiang; L Greenhill Journal: Pediatrics Date: 2005-12 Impact factor: 7.124
Authors: William F Hoffman; Meredith Moore; Raymond Templin; Bentson McFarland; Robert J Hitzemann; Suzanne H Mitchell Journal: Psychopharmacology (Berl) Date: 2006-08-17 Impact factor: 4.530
Authors: Jennifer L Perry; Erin B Larson; Jonathan P German; Gregory J Madden; Marilyn E Carroll Journal: Psychopharmacology (Berl) Date: 2004-08-27 Impact factor: 4.530
Authors: S Jamadar; E E DeVito; R E Jiantonio; S A Meda; M C Stevens; M N Potenza; J H Krystal; G D Pearlson Journal: Psychopharmacology (Berl) Date: 2012-02-04 Impact factor: 4.530
Authors: David S O'Tousa; Kaitlin T Warnock; Liana M Matson; Ojas A Namjoshi; Michael Van Linn; Veera Venkata Tiruveedhula; Meredith E Halcomb; James Cook; Nicholas J Grahame; Harry L June Journal: Addict Biol Date: 2013-10-13 Impact factor: 4.280